Your search for apixaban returned 43 results

Risk up with amiodarone vs flecainide or sotalol among seniors with atrial fibrillation receiving apixaban or rivaroxaban.

Asundexian is an investigational oral Factor XIa inhibitor.

Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban

No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons

Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery

Apixaban is a direct oral anticoagulant that relies less on kidney excretion.

Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin

Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban

Major adverse cardiopulmonary outcomes not reduced with aspirin, apixaban versus placebo for clinically stable COVID-19 outpatients

Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation